ALNY Valuation

Alnylam Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

228.430

+2.150(+0.950%)

Overview
Forecast
Valuation

ALNY Relative Valuation

ALNY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ALNY is overvalued; if below, it's undervalued.

Historical Valuation

Alnylam Pharmaceuticals Inc (ALNY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 10.91 is considered Undervalued compared with the five-year average of 17.56. The fair price of Alnylam Pharmaceuticals Inc (ALNY) is between 242.82 to 423.58 according to relative valuation methord. Compared to the current price of 228.43 USD , Alnylam Pharmaceuticals Inc is Undervalued By 5.92%.

Relative Value

Fair Zone

242.82-423.58

Current Price：228.43

5.92%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

430.47

P/B

Median3y

-1140.50

Median5y

-673.75

-0.14

FCF Yield

Median3y

-1.19

Median5y

-2.28

Competitors Valuation Multiple

The average P/S ratio for ALNY's competitors is 8.11, providing a benchmark for relative valuation. Alnylam Pharmaceuticals Inc Corp (ALNY) exhibits a P/S ratio of 10.91, which is 34.46% above the industry average. Given its robust revenue growth of 34.90%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

ALNY.O

Alnylam Pharmaceuticals Inc